Psoriasis
Conditions
Keywords
Mild to moderate psoriasis vulgaris
Brief summary
This study will look at how safe and effective, a novel agent, CT 327 cream is in treating patients with mild to moderate psoriasis vulgaris (PV). Patients will be treated twice daily for 8 weeks on specific lesions of PV and safety and symptoms of PV will be assessed throughout the treatment period.
Interventions
DRUGplacebo
1.0 g (w/w) placebo cream applied to both target lesions twice daily
DRUGCT 327
1.0 g CT 327 cream will be applied to one target lesion twice daily and 1.0 g placebo cream will be applied to the remaining target lesion twice daily
Sponsors
Creabilis SA
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Age \> 18 and \< 71 years of age * Able to give informed consent * Diagnosis of mild (affecting \< 3% BSA) to moderate (affecting \< 10% BSA) Psoriasis Vulgaris, including, at baseline visit, two symmetrical lesions of at least 10 cm2 each
Exclusion criteria
* If female of childbearing potential not using an adequate and appropriate form of contraception such as oral contraceptive; intra-uterine device (IUD); contraceptive injection, implant or patch * If female, are pregnant or lactating, or intend to become pregnant during the study period and one month thereafter * Allergy to test drug or excipients * Usage of topical corticosteroids or other topical treatments for PV within the last two weeks prior to study entry (including calcineurin inhibitor, topical H1 antihistamines, topical antimicrobials, other medicated topical agents) or herbal preparation to the area selected for treatment Within 4 weeks prior to study entry, have received systemic treatment for psoriasis (including systemic corticosteroids, nonsteroidals, immunosuppressants, or immunomodulating drugs, or treatment with light). * Received treatment with systemic or locally acting medications which might counter or influence the study aim * Presence of major medical illness requiring systemic therapy including cancers * Clinical diagnosis of bacterial infection of the skin including impetigo and abscesses * Any clinical relevant ECG abnormality * Have any clinically significant abnormal clinical laboratory test results at screening * Received any investigational drug or taking part in any clinical study within three months prior to this study * History of drug, alcohol or other substance abuse or other factors limiting the ability to co-operate and to comply with this protocol * Have concomitant dermatologic or medical condition(s) which may interfere with the investigator's ability to evaluate the subject's response to the study drug * Have immune-compromised status (such as known human immunodeficiency virus infection) * Have a history of malignancy, excluding basal cell carcinoma of the skin * Have an active intercurrent infection * Suffer from erythrodermic psoriasis, psoriasis punctata and pustular psoriasis or extended chronic stationary forms of psoriasis * Have symptoms of a clinically significant illness that may influence the outcome of the study * Have any reason which, in the opinion of the investigator, interferes with the ability of the subject to participate in or complete the trial, or which places the subject at undue risk
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvements from baseline on m-Psoriasis Area Severity Index Scale (m-PASI - modified to exclude area assessment): Proportion of subjects with a reduction in score of > 50% at Week 8 | 8 weeks |
Secondary
| Measure | Time frame |
|---|---|
| To assess the efficacy of an 8-week treatment of CT 327 vs Placebo in terms of improvements from baseline on: Proportion of subjects with a reduction in m-PASI-score of > 75% a Week 8 | 8 weeks |
Countries
Switzerland, United Kingdom, United States
Outcome results
None listed